ABSTRACT. Antibodies to glutamic acid decarboxylase (GAD), previously known as the 64-kD pancreatic islet cell autoantigen, are an important serologic marker of insulin-dependent diabetes mellitus (IDDM). Antibodies to GAD (anti-GAD) were examined in sera from Australian children with newly diagnosed IDDM (within 1 mo of diagnosis), IDDM of longer duration (mean + SD, 4.8 + 3.3 y), and in first-degree relatives, using a radioimmunoprecipitation assay with purified porcine brain GAD as antigen. Antibodies to islet cell cytoplasmic antigens (ICAb) were tested concurrently. The frequency of anti-GAD was not significantly different in children with newly diagnosed IDDM (31 of 42, 74%) and with IDDM of longer duration (14 of 21,67%), whereas ICAb were present more frequently in children with newly diagnosed IDDM (64%) than in those with longer duration IDDM (14%). In all, 90% of children with newly diagnosed IDDM had either anti-GAD or ICAb, whereas only 48% had both. For the 77 first-degree relatives, the frequency of anti-GAD was 2% (one of 44) in parents and 6% (two of 33) in siblings; ICAb were not detected in any of these relatives. The presence of anti-GAD in the majority of children with IDDM, irrespective of the duration of their disease, represents a useful diagnostic marker for IDDM, and should be of value in ascertaining individuals at risk for developing IDDM. (Pediatr Res 34: 785-790,1993) 
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Studies on antibodies to the 64-kD antigen previously were limited because of technical difficulties with measurement of the antibodies. This antigen has now been identified as GAD (8) , an enzyme that catalyzes the decarboxylation of glutamate to yaminobutyric acid, which is the major inhibitory neurotransmitter in the CNS. There are two isoforms of GAD with molecular masses of 65 kD and 67 kD (9-1 I). Outside the CNS, both forms of GAD have been found in pancreatic islet P-cells ( 1 1-13), wherein the catalytic product y-aminobutyric acid may have a paracrine role (14, 15) . The reported frequency of anti-GAD in patients with newly diagnosed IDDM of different ages varies from 22% to over 90%, depending on the method used and the source of GAD ( 1 6-19).
Given the ethnic, geographic, and age-related differences in incidence of IDDM, and the possible decrease in antibody activity with duration of disease, studies on large groups of patients among different populations, with differencages and duration of disease, will be required to assess the actual diagnostic and pathogenetic significance of anti-GAD in IDDM. In a previous study, we measured anti-GAD in Australian adolescent and adult patients with IDDM (19) , and here we report the frequency of anti-GAD in Western Australian children with newly diagnosed IDDM or IDDM of longer duration and in their family members usine, the same sensitive radioimmuno~reci~itation assav with Sera. Sera Radioimmunoprecipitation assay for anti-GAD. Anti-GAD were measured by an immunoprecipitation assay as described by Rowley et al. (19) . In brief, GAD was purified from porcine brain by affinity chromatography and iodinated with IZ5I using chloramine T. After preabsorption with normal human pooled serum, the iodinated GAD ('2SI-GAD, 100 000 cpm) was added to duplicate serum samples [25 pL in 25 pL in a Tris-Triton buffer that contained Tris 20 mM, NaCl 150 mM, Triton X-100 0.5% (wt/vol), pH 7.41. After storage overnight at 4'C, immune complexes were precipitated with protein A-Sepharose, and the radioactivity was measured. Each batch of sera tested included a positive reference serum, a high positive serum, a low positive serum, a known negative serum, and several sera from normal blood donors. Anti-GAD were expressed as designated RU by comparing counts precipitated by test sera at a dilution of 1:2 with counts precipitated by the reference serum defined to contain 100 RU of activity. Sera with a positive test for anti-GAD were titrated to end point using a 2-fold dilution for those sera with less than 80 RU and a 5-fold dilution for those sera with 80 RU or greater; accordingly, levels of anti-GAD were defined as STU, derived by the multiple ofthe number of RU at the titration end point and the actual titer as follows: STU = (RU x titer) + 2. The reason for division by 2 is that the standard serum used to derive RU is at a 2-fold dilution. Thus, in Results, sera with a positive test for anti-GAD were cited in STU and sera with a negative test for anti-GAD were cited in RU.
Immunoblotting. Immunoblotting was performed to characterize the GAD preparation used in our assays. The purified porcine brain GAD was dissolved in sample buffer containing 64 mM Tris-HC1, pH 6.8, 2.0% SDS, 10% glycerol, and 5% mercaptoethanol. The samples were boiled for 2 min and separated by 10% SDS-PAGE. The protein was electrotransferred onto a nitrocellulose membrane and blocked using 5% skimmed milk powder in PBS, pH 7.4. The nitrocellulose membrane was above, and the gel was fixed, dried, and exposed to x-ray film for 14 d.
Inhibition of irnmunoprecipitation.
To demonstrate the specificity of the binding of radioactivity in the immunoprecipitation assay, a serum was tested in the assay as described above but with the addition of about 0.05-6 ng of purified, nonlabeled GAD as inhibitor. The highest amount of the nonlabeled GAD added represented approximately 10 times the amount of IZ5I-GAD applied to the sample in the immunoprecipitation.
Test for ICAb. ICAb were detected by indirect immunofluorescence using cryostat sections from a blood group 0 human pancreas (20) . Results were expressed as JDF units based on a standard laboratory reference serum that contained 80 JDF units of ICAb. Any serum with a reactivity equal to or greater than 5 JDF units was scored as positive.
HLA-DQ genotyping. Patients were typed only for HLA-DQ alleles, inasmuch as DQ products appear to represent the primary HLA association in IDDM. HLA-DQBI typing was performed according to restriction fragment length polymorphism after enzymatic digestion of DNA and, in instances in which restriction fragment length polymorphism typing was ambiguous, confirmation was sought by amplification of DNA by the polymerase chain reaction and probing with type-specific oligonucleotides. The procedures were as described by Se jeantson el al. (2 1,22) .
Statistical analysis. The tests for statistical significance included the Mann-Whitney U test, the x2 test, or Fisher's exact test. as indicated.
RESULTS

Assay characteristics.
Using immunoblotting with monoclonal mouse and polyclonal rabbit antibodies, the purified porcine brain GAD was shown to contain two isoforms, GAD65 and GAD67 (Fig. I A) . After electrophoresis and autoradiography, the 1251-GAD used for immunoprecipitation gave a strong signal on the range of 50-80 kD, with individual proteins not identifiable ( Fig. 1 B, lane 1 ) . '251-GAD that was precipitated by four IDDM sera apparently reacted with the lower molecular mass component of GAD molecules (as judged by comparison with lane 1 in panel B).
In the inhibition-immunoprecipitation assay, the binding of serum antibody to IZ5I-GAD was inhibitable with nonlabeled exposed to GAD-6, a mouse MAb to GAD65 (lo), or K-2 (Chemicon Inc., Temecula, CA), a rabbit polyclonal antibody to B GAD67 (9), and a normal human serum (1:200). GAD-6 was ascites fluid, diluted at 1:400, and K2 was diluted at 1:200. Antibodies bound to GAD were detected using an appropriate second antibody conjugated with horseradish peroxidase, either d anti-mouse, anti-rabbit immunoglobulin or anti-human IgG (Silenus Labs, Victoria, Australia). The reaction was visualized with . P enhanced chemiluminescence using a commercial kit (Amer-mD87, sham, Buckinghamshire, UK).
Autoradiography. IZ5I-GAD used in the immunoprecipitation C%ADB~/= -52 kD -, assay and pellets, which contained antigen-antibody complexes from four sera from patients with IDDM and a known negative serum after the assay, were separated by SDS-PAGE as described Table 1 . Clinical data on children with newly diagnosed IDDM and on probands with IDDM of longer duration and their GAD, and the inhibitory effect was dose dependent, i.e. inhibition increased with increasing concentrations of nonlabeled GAD, up to 80% inhibition (Fig. 2) . The remaining 20% reactivity, at the final level of inhibition, corresponded to about 200 cpm, approximately the level of binding obtained with the known negative serum (see below). The mean (range) cprn precipitated by the positive reference serum was 2900 (1400-4600), and that by the known negative serum was 190 (60-390), for 23 separate assays. To allow comparison between assays, the positive reference serum was used as a correction factor. The coefficients of variation for interassay and intraassay replicates for a high positive control serum (100 RU) were 9% (n = 13) and 7% (n = 20), respectively, and for a low positive control serum (30 RU) were 14% (n = 13) and 8% (n = 20), respectively. The levels of anti-GAD in the 76 blood donors ranged from 4 to 18 RU and were normally distributed with mean (+SD) of 9 ( f 3 ) RU. Thus, 18 RU, which corresponds to the mean & 3 SD, was used to define the upper normal limit.
The levels of anti-GAD for three positive sera and one negative serum titrated using 2-fold dilutions were plotted against the volumes of the sera used in the immunoprecipitation assay. Below approximately 80 RU of activity, there was a linear increase in the units of anti-GAD precipitated with increasing serum concentrations, i.e. the cprn precipitated were proportional to the amount of antibody. However, a plateau was reached at around 100 RU (Fig. 3) , indicative of a limiting amount of immunoreactive antigen in the preparation of I2'I-GAD. This was confirmed by serial titration of sera with a positive test for anti-GAD for which the titers ranged from 1:2 to 1 :6250. According to the calculation (see Materials and Methods) for expressing reactivity, sera with a positive test for anti-GAD ranged from 19 to 875 000 STU of anti-GAD in the immunoprecipitation assay.
Anti-GAD in children with diabetes and relatives. The frequency of anti-GAD in children with newly diagnosed IDDM was 74% (3 1 of 42), and the mean level of anti-GAD was 7057 STU with a range of 19 to 875 000 STU. The frequency and levels of anti-GAD were not significantly different from those for probands with a longer disease duration [67% (14 of 21)], with mean of 2050 STU and a range of 30 to 16 250 STU. There were four probands with a short duration of IDDM and all were positive for anti-GAD.
One of the 44 parents (2%) and two of the 33 siblings (6%) gave a positive result for anti-GAD; thus, the overall frequency among first-degree relatives was 4% (three of 77). One relative with anti-GAD (13 750 STU) was a 35-yr-old mother with two children with IDDM; her 1 I-yr-old daughter had been diagnosed 2 y earlier, and her 9-yr-old daughter only a few days earlier, and their levels of anti-GAD were 950 STU and 46 STU, respectively. The second relative with anti-GAD (60 STU) was a 13-yr-old girl with an I I-yr-old brother with IDDM for I y whose level of anti-GAD was 675 STU. The third relative, with a minimally raised level of anti-GAD (22 STU), was a 9-yr-old boy whose 1 Iyr-old sister had IDDM for 6 y and was negative for anti-GAD. For the remainder of the relatives, the mean (f SD) units of anti-GAD were 7 (f 2) RU, range 4 to 12 RU.
ICAb. The frequency of ICAb was 64% (27 of 42; range 5-320 JDF units) in children with newly diagnosed IDDM and only 14% (three of 21; range 5-40 JDF units) in probands with a longer duration of IDDM. Three of the four probands with IDDM of short duration were positive for ICAb. All 77 firstdegree relatives were negative for ICAb.
Concordance of anti-GAD and ICAb. For newly diagnosed IDDM, the sensitivity of a positive test for anti-GAD and for ICAb was high, inasmuch as 90% of 42 children were positive for either or both. However, although there was considerable overlap in the antibody reactivity (Fig. 4) , the two antibody populations appeared to be independent; the frequency of a positive test for lCAb among the case subjects positive for anti-GAD was 65%, which was similar to the frequency for case subjects negative for anti-GAD, 63%.
Also, the frequency of anti-GAD was similar among the case subjects that were positive or negative for ICAb, 74% and 73%, respectively; however, nearly all the case subjects with a strongly positive test for ICAb (240 JDF units) were positive for anti-GAD (Fig. 5) . The frequency and levels of both anti-GAD and ICAb were higher in females than in males (Fig. 5) .
For the probands with longer duration IDDM, females (mean age f SD, 9.1 + 2.5 y) compared with males (mean age + SD, STU), but the differences were not statistically significant. The three case subjects with a positive test for ICAb among the probands with longer duration IDDM were also positive for anti-GAD and were females. There was no obvious effect of age at onset on the frequency and levels of anti-GAD or ICAb in the patients with newly diagnosed IDDM or longer duration IDDM (data not shown). Anti-GAD and HLA-DQB1 alleles. For the family study, the distributions of the high-risk HLA-DQBl alleles and the levels of anti-GAD among probands with IDDM that were positive or negative for anti-GAD and their firstdegree relatives are shown in Table 2 . Because 24 of the 25 (96%) probands presented HLA-DQB 1 *020 1 and/or *0302, an association between a positive test for anti-GAD and these alleles could not be ascertained. The frequency of HLA-DQB 1 *020 1/*0302 heterozygosity in IDDM probands was significantly higher than that in their first-degree relatives ( p < 0.001, x 2 test). The higher frequency of HLA-DQB 1 *020 1 /*0302 heterozygosity in the anti-GAD positive relatives (two of three) than that in the anti-GAD negative relatives (six of 74) was significant ( p = 0.027, Fisher's exact test). The distribution of HLA alleles appeared not to account for the female excess in frequencies of anti-GAD or ICAb in the probands.
DISCUSSION
In the present study, we measured anti-GAD by an immunoprecipitation assay. The preparation of purified porcine brain GAD that was used contained two isoforms, GAD65 and GAD67, according to immunoblotting using standard marker antibodies for these two isoforms. Similar results were obtained by analysis and sequencing of proteins that were eluted from two-dimensional SDS-PAGE preparations (23) . Although the proportions of GAD65 and GAD67 precipitated by the antibodies in IDDM sera were not ascertained in this study, it is known that antibodies in such sera may react with either one or both isoforms (16) . However, it appeared from our study that the 65-kD isoform was the main reactant, as found also by others (13) . It was shown that iodinated GAD and nonlabeled GAD were antigenically similar using inhibition of the immunoprecipitation assay, wherein nonlabeled GAD inhibited the binding of anti-GAD to '"I-GAD in a dose-dependent manner. This inhibitory effect validated the specificity of binding of anti-GAD to the "' I-GAD in our assay.
The study population, children with IDDM and their firstdegree relatives, were from Perth in Western Australia, which is an area with a midrange of IDDM incidence for the world (1 3.2 per 100 000 persons/y) (24) . Seventy-four percent of children with newly diagnosed IDDM had anti-GAD. The frequency of anti-GAD was similar to that found in Australian adult patients with IDDM (19, 25) and was similar to the frequency of antibodies to the 64-kD autoantigen in previous studies (4, 26) . In agreement with previous findings (2, 27) , the titer and prevalence of ICAb decreased with increasing duration of disease; 64% of children with newly diagnosed IDDM were positive for ICAb in contrast to 14% of those with IDDM of longer duration. However, there was no significant difference in the frequency or the levels of anti-GAD according to disease duration. Anti-GAD persists in the majority of patients for up to 10-20 y after diagnosis (19, 26) , albeit with some decrease in antibody frequency (22) , although this was not observed in the present study. The persistence of anti-GAD in patients with IDDM even after presumed destruction of most if not all pancreatic islet P-cells is noteworthy. This may reflect either the existence of some GAD in residual islet cell tissue (28) , ongoing autoantigenic stimulation by GAD in extrapancreatic sites, or conceivably stimulation by exogenous antigens that have some structural homology with GAD.
Immunotrapping enzyme activity assays have shown that anti-GAD are demonstrable mostly in sera with higher titers of ICAb (6, 17, 18) . Similarly, we found that nearly all patients with high titers of ICAb had anti-GAD, but patients with high levels of anti-GAD did not necessarily have ICAb. Although anti-GAD and ICAb appear to be independent populations of antibodies, anti-GAD would contribute in part to ICAb activity, because ICAb activity could be removed by preabsorption of sera with a rat brain homogenate that contained GAD (29) .
Gender differences in the frequency of autoimmune diseases are of interest. The frequency is mostly greater in females, which is attributable to hormonal effects that would operate after puberty. Autoimmune diabetes is exceptional, with males predominating slightly, perhaps because of the onset of disease in childhood. In regard to autoantibodies, anti-GAD and ICAb in IDDM have a predominance in females when there is coexisting autoimmunity, clinical or serologic (2, 17, 30) . In the present study on children without other known autoimmune diseases, the levels of anti-GAD and the frequency of ICAb were greater in females than males; there appeared to be no obvious influence of age at onset or distribution of HLA alleles on the higher levels of anti-GAD and higher frequency of ICAb in females. The higher frequency in our study of levels of anti-GAD and ICAb in girls might be an artifact related to the small number of cases studied; however, the frequency in IDDM of ICAb is reported to be significantly higher in females than in males, at least when the onset of IDDM is after the age of 30 y (31), and we note a report of a nonsignificantly higher frequency in females than males with IDDM of autoantibodies to the 64-kD antigen (32) . Of interest, more girls than boys were diagnosed with IDDM (24) .
The presence of anti-GAD or ICAb in healthy persons may be a sign of ongoing destruction of islet cells and, at this stage, intervention could halt the autoimmune process. Positivity for ICAb denotes an increased but not absolute risk of developing IDDM, whether or not any family member has IDDM: the predictive value of ICAb is especially high in firstdegree relatives of patients with IDDM. In different studies, the frequency of ICAb in first-degree relatives of patients with IDDM has ranged from 0.9 to 6% (33) (34) (35) . The risk of developing IDDM in firstdegree relatives of patients with IDDM has been estimated to be about 1 % in those negative for ICAb, compared with 40-70% in those positive for ICAb, depending on the titer of ICAb (26, 35, 36) . ICAb were not detected in any of the first-degree relatives in our study, presumably because of the relatively small number of subjects tested. However, the frequency of anti-GAD was 2% in parents and 6% in siblings of children with IDDM.
Concordance rates of IDDM are about 36% in identical twins (37) and 15% in HLA-identical siblings (38) . These low rates, together with marked geographic differences in incidence and prevalence of IDDM (39) , clearly indicate that environmental as well as genetic factors contribute to the pathogenesis of IDDM. In Caucasians, the HLA-associated DQ genotypes DQB 1 *0302 and DQB 1 *020 1, together with DR3 and DR4, are associated with IDDM (38, 40) . Moreover, each of the genotypes has been linked to an increased prevalence of anti-GAD in Caucasian patients with IDDM (2 1,22) . In the present study, most probands had these high-risk genotypes, and the frequency of HLA-DQB 1 *020 1 /*0302 heterozygosity was significantly higher in the probands than in the relatives. The HLA-DQB 1 *020 1/*0302 heterozygosity was also observed to be higher in anti-GADpositive relatives than in anti-GAD-negative relatives, but we recognize the small number of cases available for analysis, and more relatives are being recruited to reexamine this finding.
In conclusion, testing for anti-GAD could provide a highly discriminatory ascertainment of risk for IDDM (18) , especially if used together with detection of ICAb and high-risk genotypes (41) . This will be increasingly relevant with the development of immunologically based interventions at the preclinical stage of IDDM.
